Gleason Score News and Research RSS Feed - Gleason Score News and Research

Researchers discover new gene subgroup that drives prostate cancer

Researchers discover new gene subgroup that drives prostate cancer

Prostate cancer researchers have drawn a molecular portrait that provides the first complete picture of localized, multi-focal disease within the prostate and also unveils a new gene subgroup driving it. [More]
Research may offer new targets for diagnosing, treating advanced prostate cancer

Research may offer new targets for diagnosing, treating advanced prostate cancer

Researchers with the Indiana University School of Medicine have identified a molecule that promotes metastasis of advanced prostate cancer to the bone, an incurable condition that significantly decreases quality of life. [More]
New studies to improve prostate cancer detection to be presented at AUA annual meeting

New studies to improve prostate cancer detection to be presented at AUA annual meeting

Five new studies evaluating the use of imaging and urine-based biomarkers as ways to improve prostate cancer detection will be presented during the 110th Annual Scientific Meeting of the American Urological Association (AUA). [More]
Active surveillance appears to be safer management strategy for prostate cancer patients

Active surveillance appears to be safer management strategy for prostate cancer patients

Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer will be presented during the 110th Annual Scientific Meeting of the American Urological Association. [More]
Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. [More]
GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy. [More]
Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiation therapy treatment, according to a study published in the February 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology. [More]
Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

GenomeDx Biosciences today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the company's Decipher prostate cancer classifier. [More]
Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer. [More]
Prostate biopsy method impacts cancer risk profile

Prostate biopsy method impacts cancer risk profile

Prostate cancers that are classified as “low risk” based on conventional prostate biopsy and histology are frequently found to be higher risk when assessed using the newer targeted biopsy method, US researchers have warned. [More]
ProMark test for prostate cancer meets primary endpoint

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease. [More]
Vitamin D deficiency predicts prostate biopsy outcomes

Vitamin D deficiency predicts prostate biopsy outcomes

Men with vitamin D deficiency are more likely than men with normal levels to test positive for prostate cancer on biopsy, and to have aggressive disease, US researchers have found. [More]
Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center. [More]

Invasive 3D mapping biopsies detect ultrasound-guided biopsies miss prostate cancers

Ultrasound-guided biopsies miss prostate cancers that are detected by the slightly more expensive and slightly more invasive 3D mapping biopsies. For example, in a 2006 study of 180 men diagnosed with early stage prostate cancer via ultrasound-guided biopsy, nearly a quarter were upgraded to a more clinically significant stage of disease after 3D mapping biopsy found pockets of cancer the first technique had missed. [More]
Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics, Inc. today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients. [More]
Nomogram predicts overdiagnosis in prostate cancer screening

Nomogram predicts overdiagnosis in prostate cancer screening

US researchers have developed a nomogram which they say can be used to predict whether prostate cancer has been overdiagnosed in individual patients diagnosed following prostate-specific antigen screening. [More]
Higher levels of physical activity reduces risk of prostate cancer recurrence, mortality

Higher levels of physical activity reduces risk of prostate cancer recurrence, mortality

Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21. [More]
Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence. [More]
Perioperative analgesia may improve prostate cancer outcomes

Perioperative analgesia may improve prostate cancer outcomes

Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found. [More]
Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up. [More]
Advertisement
Advertisement